剂量均匀性在现代乳腺癌大分割放疗中的关键作用
本文综述乳腺癌放疗从常规分割向大分割及超大分割演变的历程,指出随着分次剂量增大,剂量不均匀性的生物学影响被放大,容积控制高剂量区对美容效果和晚期毒性至关重要。文中汇总标志性试验的剂量学参数,强调V105%<5%–10%、V107%<2%、最大剂量<110%等指标对大分割成功实施的关键作用,并指出在均匀性优化前提下乳房大小而非分割方案决定美容风险。
要点
- 分次剂量增大时剂量不均匀性的生物学影响被放大,高剂量区容积控制对美容和晚期效应至关重要。
- 关键剂量学指标包括V105%<5%–10%、V107%<2%、最大剂量<110%。
- 均匀性优化后乳房大小而非分割方案决定美容风险。
核心结论
- 剂量均匀性应被视为当代乳腺癌放疗的基本要求而非次要终点。
研究设计与样本
- 本综述梳理从二维中心轴处方到三维容积优化的技术演进,并分析标志性试验的剂量学参数。
主要发现
- 多项随机试验显示大分割在疾病控制和美容效果上非劣于常规分割。
- 分次剂量增大使剂量不均匀性的生物学影响被放大,容积控制高剂量区对美容和减少晚期效应至关重要。
- 标志性试验的剂量学参数显示剂量均匀性的重要性,V105%<5%–10%、V107%<2%、最大剂量<110%对大分割成功实施关键。
- 在均匀性优化前提下,乳房大小而非分割方案决定美容风险。
关键数值与推荐
- V105%<5%–10%。
- V107%<2%。
- 最大剂量<110%。
临床怎么用
- 使用现代计划技术达到上述剂量均匀性标准,并将其作为计划设计的基本要求。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The evolution of breast cancer radiation therapy has witnessed a paradigm shift from conventional fractionation to hypofractionation and now ultrahypofractionation, with multiple randomized trials demonstrating noninferiority in both disease control and cosmetic outcomes. A central, yet underemphasized, determinant of this success is plan optimization by dose homogeneity. As fraction size increases, the biological impact of dose heterogeneity becomes magnified, making volumetric control of high-dose regions essential for both cosmesis and reducing late effects. This comprehensive review traces the progression from 2-dimensional central axis prescriptions to 3-dimensional volumetric optimization, examining how technological advances have enabled safe delivery of larger fraction sizes, partially through the ability to improve dose homogeneity. Dosimetric parameters across landmark trials have shown the importance of dose homogeneity, and metrics such as V105% <5% to 10%, V107% <2%, and maximum dose <110% are critical for successful hypofractionation. The evidence reveals that breast size, not fractionation schedule, drives cosmetic risk when homogeneity is optimized. We provide practical recommendations for achieving these standards using modern planning techniques, emphasizing that dose homogeneity must be considered a fundamental requirement, not a secondary endpoint, in contemporary breast radiation therapy.
引用
- Sourial F, Champ C, Beriwal S, et al. The Critical Role of Dose Homogeneity in Modern Breast Hypofractionation. Int J Radiat Oncol Biol Phys. 2026. PMID: 41554414. doi:10.1016/j.ijrobp.2026.01.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。